Omeros nets $32.3 million for surgical drugs
This article was originally published in Scrip
Omeros earned net proceeds of $32.3 million in a common stock offering of 3.4 million shares priced at $10.25 per share that closed on 2 July. The Seattle, Washington-based company generated $4.2 million above the net gain anticipated when the offering went to market on 27 June, because all 439,024 shares granted to the underwriters to cover overallotments were sold.
You may also be interested in...
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.
Biopharma executives discussed their strategies for treating chronic diseases during the Cell and Gene Meeting on the Mesa, including R&D and regulatory considerations.